Serum cardiac troponin I is a candidate biomarker for cardiomyopathy in Duchenne and Becker muscular dystrophies
- 16 February 2022
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 65 (5) , 521-530
Abstract
Introduction/Aims: Serum cardiac troponin I (cTnI), its relation to cardiomyopathy, and the contribution of the ACTN3 genotype to serum levels of cTnI in Duchenne and Becker muscular dystrophy (DMD and BMD, respectively) remain unknown. In this study we aimed to reveal the characteristics of cTnI, assess whether cTnI is a biomarker for cardiomyopathy in these dystrophinopathies, and evaluate the contribution of the ACTN3 genotype to the serum levels of cTnI in DMD patients.Methods: Serum cTnI values obtained from 127 DMD and 47 BMD patients were analyzed retrospectively. The relationship between cTnI and echocardiography data or the ACTN3 XX genotype was assessed.Results: The cTnI levels and proportion of patients with abnormal cTnI levels were significantly higher among DMD patients than BMD, especially in the second decade of life. In DMD, the cTnI level reached a maximum at 13 years, and left ventricular ejection fraction (LVEF) became abnormal approximately 1 year subsequently. In BMD, the cTnI level peaked at the age of 14 years, and LVEF became abnormal 3 years later. Decreased LVEF was observed after cTnI elevation in both populations. cTnI levels by age in DMD patients with the ACTN3 XX genotype tended to increase significantly and early.Discussion: Myocardial injury indicated by cTnI elevation was more common and severe in DMD patients. cTnI elevation preceding cardiac dysfunction may represent an early phase of cardiomyopathy progression and may be a biomarker for early detection of cardiomyopathy in these dystrophinopathies. The ACTN3 XX genotype may be a risk factor for early myocardial injury.Keywords
This publication has 34 references indexed in Scilit:
- Characterisation of a highly sensitive troponin I assay and its application to a cardio-healthy populationClinical Chemistry and Laboratory Medicine (CCLM), 2012
- Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral centerJournal of Human Genetics, 2010
- Cardiac troponin I for accurate evaluation of cardiac status in myopathic patientsBrain and Development, 2008
- Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?The International Journal of Cardiovascular Imaging, 2008
- Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: A comparative study from the Pediatric Cardiomyopathy RegistryAmerican Heart Journal, 2008
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart FailureClinical Chemistry, 2007
- Cardiac troponin I for accurate evaluation of cardiac status in myopathic patientsBrain and Development, 2007
- National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary SyndromesClinical Chemistry, 2007
- Genetic Predictors and Remodeling of Dilated Cardiomyopathy in Muscular DystrophyCirculation, 2005
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJACC, 2000